candesartan has been researched along with Hypertension, Renal in 27 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Hypertension, Renal: Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with candesartan, an angiotensin-II-receptor blocker (ARB), controlled both hypertension and proteinuria satisfactorily without worsening of his renal function." | 5.32 | A case of nephrotic syndrome associated with renovascular hypertension successfully treated with candesartan. ( Chinda, J; Hasebe, N; Hirayama, T; Imamoto, C; Kikuchi, K; Okada, M; Takahashi, F; Takeuchi, T, 2003) |
| "We previously reported that the angiotensin II type 1 receptor antagonist candesartan was effective in reducing blood pressure and microalbuminuria in hypertensive patients with diabetic nephropathy after angiotensin-converting enzyme (ACE) inhibitors were replaced due to side effects." | 5.10 | Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. ( Hayashi, K; Saruta, T; Sato, A; Tabata, M, 2003) |
| " We subsequently used full dose ramipril, candesartan and aliskiren under a close monitoring of kidney function and electrolytes and examined the effect on proteinuria, clinical course and tolerability over 12 months." | 3.75 | Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. ( Amann, K; Frank, H; Freiberger, V; Heemann, U, 2009) |
| "Rats with adenine-induced chronic renal failure (A-CRF) develop metabolic and cardiovascular abnormalities resembling those in patients with chronic kidney disease." | 1.39 | Rats with adenine-induced chronic renal failure develop low-renin, salt-sensitive hypertension and increased aortic stiffness. ( Carlström, M; Grimberg, E; Guron, G; Johansson, ME; Lundberg, JO; Lundgren, J; Nguy, L; Nilsson, H; Teerlink, T, 2013) |
| "Candesartan treatment significantly increased the level of plasma Ile(5)-Ang II (24." | 1.36 | Angiotensin II type 1 receptor-mediated augmentation of urinary excretion of endogenous angiotensin II in Val5-angiotensin II-infused rats. ( Navar, LG; Seth, DM; Shao, W, 2010) |
| "The metabolic syndrome is a risk factor for the development of chronic kidney disease." | 1.35 | Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. ( Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N, 2008) |
| "Type 1 diabetes was induced in rats by intraperitoneally injecting spontaneously hypertensive rats with streptozotocin." | 1.35 | Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats. ( Hayashi, K; Iigaya, K; Itoh, H; Kamayachi, T; Kumagai, H; Onami, T; Osaka, M; Sakata, K; Saruta, T; Takimoto, C, 2008) |
| "Treatment with candesartan, an angiotensin-II-receptor blocker (ARB), controlled both hypertension and proteinuria satisfactorily without worsening of his renal function." | 1.32 | A case of nephrotic syndrome associated with renovascular hypertension successfully treated with candesartan. ( Chinda, J; Hasebe, N; Hirayama, T; Imamoto, C; Kikuchi, K; Okada, M; Takahashi, F; Takeuchi, T, 2003) |
| "Candesartan treatment prevented the hypertension (87 +/- 3 mmHg) and led to increased plasma Ang II concentrations (441 +/- 27 fmol/ml), but prevented increases in kidney (120 +/- 15 fmol/g) and renal interstitial fluid (2." | 1.32 | Angiotensin II type 1 receptor-mediated augmentation of renal interstitial fluid angiotensin II in angiotensin II-induced hypertension. ( Navar, LG; Nishiyama, A; Seth, DM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (22.22) | 18.2507 |
| 2000's | 18 (66.67) | 29.6817 |
| 2010's | 3 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nguy, L | 1 |
| Johansson, ME | 1 |
| Grimberg, E | 1 |
| Lundgren, J | 1 |
| Teerlink, T | 1 |
| Carlström, M | 1 |
| Lundberg, JO | 1 |
| Nilsson, H | 1 |
| Guron, G | 1 |
| Namikoshi, T | 1 |
| Tomita, N | 1 |
| Satoh, M | 1 |
| Haruna, Y | 1 |
| Kobayashi, S | 1 |
| Komai, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Banday, AA | 1 |
| Lokhandwala, MF | 1 |
| Takimoto, C | 1 |
| Kumagai, H | 1 |
| Osaka, M | 1 |
| Sakata, K | 1 |
| Onami, T | 1 |
| Kamayachi, T | 1 |
| Iigaya, K | 1 |
| Hayashi, K | 2 |
| Saruta, T | 2 |
| Itoh, H | 1 |
| Freiberger, V | 1 |
| Amann, K | 1 |
| Heemann, U | 1 |
| Frank, H | 1 |
| Shao, W | 1 |
| Seth, DM | 2 |
| Navar, LG | 4 |
| Nakagawa, N | 1 |
| Fujino, T | 1 |
| Kabara, M | 1 |
| Matsuki, M | 1 |
| Chinda, J | 2 |
| Kikuchi, K | 2 |
| Hasebe, N | 2 |
| Ueno, T | 1 |
| Kaname, S | 1 |
| Takaichi, K | 1 |
| Nagase, M | 1 |
| Tojo, A | 1 |
| Onozato, ML | 1 |
| Fujita, T | 1 |
| Takahashi, F | 1 |
| Okada, M | 1 |
| Takeuchi, T | 1 |
| Hirayama, T | 1 |
| Imamoto, C | 1 |
| Yokota, K | 1 |
| Kishida, M | 1 |
| Ogura, T | 1 |
| Suzuki, J | 1 |
| Otsuka, F | 1 |
| Mimura, Y | 1 |
| Takeda, M | 1 |
| Nakamura, Y | 1 |
| Makino, H | 1 |
| Nishiyama, A | 1 |
| Yao, K | 1 |
| Sato, H | 1 |
| Ina, Y | 1 |
| Suzuki, K | 1 |
| Ohno, T | 1 |
| Shirakura, S | 1 |
| Sato, A | 1 |
| Tabata, M | 1 |
| Gross, O | 1 |
| Schulze-Lohoff, E | 1 |
| Koepke, ML | 1 |
| Beirowski, B | 1 |
| Addicks, K | 1 |
| Bloch, W | 1 |
| Smyth, N | 1 |
| Weber, M | 1 |
| Ishimitsu, T | 1 |
| Kobayashi, T | 1 |
| Honda, T | 1 |
| Takahashi, M | 1 |
| Minami, J | 1 |
| Ohta, S | 1 |
| Inada, H | 1 |
| Yoshii, M | 1 |
| Ono, H | 1 |
| Matsuoka, H | 1 |
| Nakamura, T | 3 |
| Kanno, Y | 1 |
| Takenaka, T | 1 |
| Suzuki, H | 1 |
| Franco, M | 1 |
| Martínez, F | 1 |
| Rodríguez-Iturbe, B | 1 |
| Johnson, RJ | 1 |
| Santamaría, J | 1 |
| Montoya, A | 1 |
| Nepomuceno, T | 1 |
| Bautista, R | 1 |
| Tapia, E | 1 |
| Herrera-Acosta, J | 1 |
| Vanecková, I | 1 |
| Kopkan, L | 1 |
| Husková, Z | 1 |
| Vanourková, Z | 1 |
| Schejbalová, S | 1 |
| Cervenka, L | 4 |
| Kramer, HJ | 2 |
| Li, XC | 2 |
| Widdop, RE | 2 |
| Jarrott, B | 1 |
| Honma, H | 1 |
| Ikeda, Y | 1 |
| Kuroyanagi, R | 1 |
| Takano, H | 2 |
| Obata, J | 2 |
| Sato, T | 1 |
| Kimura, H | 2 |
| Yoshida, Y | 2 |
| Tamura, K | 1 |
| Taal, MW | 1 |
| Brenner, BM | 1 |
| Harrison-Bernard, LM | 1 |
| Imig, JD | 1 |
| Mitchell, KD | 1 |
| Wada, T | 1 |
| Inada, Y | 1 |
| Ojima, M | 1 |
| Sanada, T | 1 |
| Shibouta, Y | 1 |
| Nishikawa, K | 1 |
| Naito, A | 1 |
| Shimizu, F | 1 |
| Guo, DF | 1 |
| Inagami, T | 1 |
| Malý, J | 1 |
| Heller, J | 1 |
2 reviews available for candesartan and Hypertension, Renal
| Article | Year |
|---|---|
ACE-I vs angiotensin II receptor antagonists: prevention of renal injury in chronic rat models.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1999 |
Renal responses to AT1 receptor blockade.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2000 |
4 trials available for candesartan and Hypertension, Renal
| Article | Year |
|---|---|
Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles | 2011 |
Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2003 |
Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe | 2005 |
An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2005 |
21 other studies available for candesartan and Hypertension, Renal
| Article | Year |
|---|---|
Rats with adenine-induced chronic renal failure develop low-renin, salt-sensitive hypertension and increased aortic stiffness.
Topics: Adenine; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Arterial Pressure; Benzimidazoles; | 2013 |
Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dietary Protei | 2008 |
Loss of biphasic effect on Na/K-ATPase activity by angiotensin II involves defective angiotensin type 1 receptor-nitric oxide signaling.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2008 |
Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2008 |
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.
Topics: Adult; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An | 2009 |
Angiotensin II type 1 receptor-mediated augmentation of urinary excretion of endogenous angiotensin II in Val5-angiotensin II-infused rats.
Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazol | 2010 |
LOX-1, an oxidized low-density lipoprotein receptor, was upregulated in the kidneys of chronic renal failure rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
A case of nephrotic syndrome associated with renovascular hypertension successfully treated with candesartan.
Topics: Aged; Angiography, Digital Subtraction; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2003 |
Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2003 |
Angiotensin II type 1 receptor-mediated augmentation of renal interstitial fluid angiotensin II in angiotensin II-induced hypertension.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Ag | 2003 |
Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol | 2003 |
Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2004 |
Angiotensin II, interstitial inflammation, and the pathogenesis of salt-sensitive hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2006 |
Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Benzimidazoles; Bip | 2007 |
Regional hemodynamic effects of the AT1 receptor antagonist CV-11974 in conscious renal hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Consc | 1995 |
Regional haemodynamic effects of the novel AT1 receptor antagonist, CV-11974, in conscious rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Consc | 1994 |
Renal protective effects of angiotensin II receptor I antagonist CV-11974 in spontaneously hypertensive stroke-prone rats (SHR-sp).
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cereb | 1994 |
Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Topics: Administration, Oral; Angiotensin I; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonis | 1996 |
Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Benzimidazoles; Biph | 2000 |
Role of nNOS in regulation of renal function in angiotensin II-induced hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 2001 |